sulfonamides

Summary

Summary: A group of compounds that contain the structure SO2NH2.

Top Publications

  1. Winkler J, Rand M, Schmugge M, Speer O. Omi/HtrA2 and XIAP are components of platelet apoptosis signalling. Thromb Haemost. 2013;109:532-9 pubmed publisher
    ..These results indicate that platelets have a functional intrinsic apoptotic-signalling pathway including the pro-apoptotic protease Omi/HtrA2 and its target protein XIAP...
  2. de Lastours V, Ferrari Rafael De Silva E, Daudon M, Porcher R, Loze B, Sauvageon H, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68:1850-6 pubmed publisher
    ..Atazanavir has been associated with kidney stones and renal failure. We measured urine and plasma concentrations of recent protease inhibitors (PIs) and searched for PI crystals in the urine of asymptomatic patients...
  3. Azab M, Youssef M, El Bordany E. Synthesis and antibacterial evaluation of novel heterocyclic compounds containing a sulfonamido moiety. Molecules. 2013;18:832-44 pubmed publisher
    ..The newly synthesized compounds were tested for antibacterial activity, whereby eight compounds were found to have high activities. ..
  4. Gerullis H, Eimer C, Ecke T, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs. 2013;24:422-5 pubmed publisher
    ..This phase I study showed that combined therapy of daily pazopanib (200 mg) and vinflunine (280/320 mg/m) every 3 weeks is poorly tolerated in patients with refractory advanced urothelial cancer. ..
  5. Bertin Ciftci J, Barre B, Le Pen J, Maillet L, Couriaud C, Juin P, et al. pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737. Cell Death Differ. 2013;20:755-64 pubmed publisher
    ..Thus, caspases contribute to trigger the mitochondrial apoptotic pathway by coupling Bcl-2/Bcl-xL inhibition to that of Mcl-1, via the pRb/E2F-1-dependent induction of Noxa. ..
  6. Madácsi R, Kanizsai I, Fehér L, Gyuris M, Ozsvári B, Erdélyi A, et al. Aromatic sulfonamides containing a condensed piperidine moiety as potential oxidative stress-inducing anticancer agents. Med Chem. 2013;9:911-9 pubmed
    ..Among the tested sulfonamides, compounds 21, 22, 23, 35 and 41 exhibited 100% cytotoxic effects with low (< 10 µM) EC50 values on K562 ..
  7. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie M, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24:120-9 pubmed publisher
    ..Importantly, these two classes of inhibitor further enhanced tumor response in combination therapy with tamoxifen. Collectively, our findings provide a rationale for the clinical evaluation of BH3 mimetics in therapy for breast cancer. ..
  8. Nguyen Q, McMenemy M, Realini T, Whitson J, Goode S. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther. 2013;29:290-7 pubmed publisher
    ..2% (BBFC) with that of its component medications, brinzolamide and brimonidine, in patients with open-angle glaucoma or ocular hypertension...
  9. Haq R, Shoag J, Andreu Pérez P, Yokoyama S, Edelman H, Rowe G, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1? and MITF. Cancer Cell. 2013;23:302-15 pubmed publisher
    ..Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxidative phosphorylation. Our data thus identify an adaptive metabolic program that limits the efficacy of BRAF inhibitors. ..
  10. Feld J, Kowdley K, Coakley E, Sigal S, Nelson D, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-603 pubmed publisher
    ..In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis...

Detail Information

Publications62

  1. Winkler J, Rand M, Schmugge M, Speer O. Omi/HtrA2 and XIAP are components of platelet apoptosis signalling. Thromb Haemost. 2013;109:532-9 pubmed publisher
    ..These results indicate that platelets have a functional intrinsic apoptotic-signalling pathway including the pro-apoptotic protease Omi/HtrA2 and its target protein XIAP...
  2. de Lastours V, Ferrari Rafael De Silva E, Daudon M, Porcher R, Loze B, Sauvageon H, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68:1850-6 pubmed publisher
    ..Atazanavir has been associated with kidney stones and renal failure. We measured urine and plasma concentrations of recent protease inhibitors (PIs) and searched for PI crystals in the urine of asymptomatic patients...
  3. Azab M, Youssef M, El Bordany E. Synthesis and antibacterial evaluation of novel heterocyclic compounds containing a sulfonamido moiety. Molecules. 2013;18:832-44 pubmed publisher
    ..The newly synthesized compounds were tested for antibacterial activity, whereby eight compounds were found to have high activities. ..
  4. Gerullis H, Eimer C, Ecke T, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs. 2013;24:422-5 pubmed publisher
    ..This phase I study showed that combined therapy of daily pazopanib (200 mg) and vinflunine (280/320 mg/m) every 3 weeks is poorly tolerated in patients with refractory advanced urothelial cancer. ..
  5. Bertin Ciftci J, Barre B, Le Pen J, Maillet L, Couriaud C, Juin P, et al. pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737. Cell Death Differ. 2013;20:755-64 pubmed publisher
    ..Thus, caspases contribute to trigger the mitochondrial apoptotic pathway by coupling Bcl-2/Bcl-xL inhibition to that of Mcl-1, via the pRb/E2F-1-dependent induction of Noxa. ..
  6. Madácsi R, Kanizsai I, Fehér L, Gyuris M, Ozsvári B, Erdélyi A, et al. Aromatic sulfonamides containing a condensed piperidine moiety as potential oxidative stress-inducing anticancer agents. Med Chem. 2013;9:911-9 pubmed
    ..Among the tested sulfonamides, compounds 21, 22, 23, 35 and 41 exhibited 100% cytotoxic effects with low (< 10 µM) EC50 values on K562 ..
  7. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie M, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24:120-9 pubmed publisher
    ..Importantly, these two classes of inhibitor further enhanced tumor response in combination therapy with tamoxifen. Collectively, our findings provide a rationale for the clinical evaluation of BH3 mimetics in therapy for breast cancer. ..
  8. Nguyen Q, McMenemy M, Realini T, Whitson J, Goode S. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther. 2013;29:290-7 pubmed publisher
    ..2% (BBFC) with that of its component medications, brinzolamide and brimonidine, in patients with open-angle glaucoma or ocular hypertension...
  9. Haq R, Shoag J, Andreu Pérez P, Yokoyama S, Edelman H, Rowe G, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1? and MITF. Cancer Cell. 2013;23:302-15 pubmed publisher
    ..Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxidative phosphorylation. Our data thus identify an adaptive metabolic program that limits the efficacy of BRAF inhibitors. ..
  10. Feld J, Kowdley K, Coakley E, Sigal S, Nelson D, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-603 pubmed publisher
    ..In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis...
  11. Corcoran R, Cheng K, Hata A, Faber A, Ebi H, Coffee E, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013;23:121-8 pubmed publisher
  12. Grandemange E, Fournel S, Woehrle F. Efficacy and safety of cimicoxib in the control of perioperative pain in dogs. J Small Anim Pract. 2013;54:304-12 pubmed publisher
    ..To determine the efficacy and safety of cimicoxib (Cimalgex®; Vétoquinol SA) for the control of perioperative pain in dogs...
  13. Weigelt B, Warne P, Lambros M, Reis Filho J, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013;19:3533-44 pubmed publisher
    ..Inhibition of p110? alone may not be sufficient to sensitize PTEN-mutant EEC cells and combination with other targeted agents may be required. ..
  14. Abel E, Basile K, Kugel C, Witkiewicz A, Le K, Amaravadi R, et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest. 2013;123:2155-68 pubmed publisher
  15. Vandenberg C, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013;121:2285-8 pubmed publisher
    ..When ABT-737 was combined with the proteosome inhibitor bortezomib or CDK inhibitor purvalanol, many treated animals achieved long-term remission...
  16. van Heumen B, Roelofs H, Vink Börger M, Dekker E, Mathus Vliegen E, Dees J, et al. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial. Orphanet J Rare Dis. 2013;8:118 pubmed publisher
    ..We performed a randomized, double-blind, placebo-controlled trial to investigate the effect of celecoxib and UDCA co-treatment on duodenal adenomatosis in patients with FAP...
  17. Rami M, Dubois L, Parvathaneni N, Alterio V, van Kuijk S, Monti S, et al. Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J Med Chem. 2013;56:8512-20 pubmed publisher
    ..Such CA inhibitors, specifically targeting the tumor-associated isoforms, are candidates for novel treatment strategies against hypoxic tumors overexpressing extracellular CA isozymes. ..
  18. Beck D, Niessner H, Smalley K, Flaherty K, Paraiso K, Busch C, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal. 2013;6:ra7 pubmed publisher
    ..Thus, thapsigargin or other inducers of ER stress may be useful in combination therapies to overcome vemurafenib resistance. ..
  19. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann K, Speicher D, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013;23:811-25 pubmed publisher
    ..Our findings support a two-tiered approach combining anticancer agents that eliminate rapidly proliferating melanoma cells with inhibitors of the drug-resistant slow-cycling subpopulation. ..
  20. Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky L, Cohen G. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. 2013;20:1475-84 pubmed publisher
    ..Expanded medicinal chemistry iteration, as performed for the ABT series, may likewise improve the potency and specificity of the evaluated MCL-1 inhibitors. ..
  21. Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-31 pubmed publisher
    ..This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy...
  22. Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202-8 pubmed publisher
    ..These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers...
  23. Pili R, Qin R, Flynn P, Picus J, Millward M, Ho W, et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013;11:477-83 pubmed publisher
    ..A 2-stage phase II study was conducted to assess the activity and toxicity profile of pazopanib in patients with metastatic, urothelial carcinoma...
  24. Jacobson I, Dore G, Foster G, Fried M, Radu M, Rafalsky V, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403-13 pubmed publisher
    ..The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection...
  25. Fiskus W, Verstovsek S, Manshouri T, Smith J, Peth K, Abhyankar S, et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther. 2013;12:577-88 pubmed publisher
    ..These findings create a compelling rationale to determine the in vivo activity of dual PI3K/mTOR inhibitors in combination with JAK inhibitors against myelofibrosis HPCs...
  26. Shimizu A, Takada H, Koike T, Takeshita A, Saha M, Rinawati -, et al. Ubiquitous occurrence of sulfonamides in tropical Asian waters. Sci Total Environ. 2013;452-453:108-15 pubmed publisher
    Seven sulfonamides, trimethoprim, five macrolides, lincomycin and three tetracyclines were measured in 150 water samples of sewage, livestock and aquaculture wastewater, and river and coastal waters, in five tropical Asian countries...
  27. Alafeefy A, Isik S, Abdel Aziz H, Ashour A, Vullo D, Al Jaber N, et al. Carbonic anhydrase inhibitors: benzenesulfonamides incorporating cyanoacrylamide moieties are low nanomolar/subnanomolar inhibitors of the tumor-associated isoforms IX and XII. Bioorg Med Chem. 2013;21:1396-403 pubmed publisher
    ..Generally, electron donating groups in the starting aldehyde reagent favored CA IX and XII inhibition, whereas halogeno, methoxy and dimethylamino moieties led to very potent CA XII inhibitors. ..
  28. Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther. 2013;12:1691-700 pubmed publisher
    ..These data are critical advances toward the discovery of novel anticancer agents. ..
  29. Kim H, Hong Y, Park J, Sharma V, Cho S. Sulfonamides and tetracyclines in livestock wastewater. Chemosphere. 2013;91:888-94 pubmed publisher
    Antibiotics (sulfonamides and tetracyclines) have attractive increasing attention due to their persistence for a long time, which lead to concern of widespread antibiotic resistant bacteria and resistance genes in the aquatic environment...
  30. Wang H, Yang Y, Shen H, Gu J, Li T, Li X. ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells. PLoS ONE. 2012;7:e52483 pubmed publisher
    ..Our data imply that combination of ABT-737 and conventional radiation therapy might represent a highly effective therapeutic approach for future treatment of cervical cancer. ..
  31. Delcaru C, Podgoreanu P, Alexandru I, Popescu N, Măruţescu L, Bleotu C, et al. Antibiotic Resistance and Virulence Phenotypes of Recent Bacterial Strains Isolated from Urinary Tract Infections in Elderly Patients with Prostatic Disease. Pathogens. 2017;6: pubmed publisher
    ..Increased resistance rates to tetracyclines, quinolones, and sulfonamides were registered...
  32. Huang R, Tao X, Wan C, Li S, Xu H, Xu F, et al. In vitro probiotic characteristics of Lactobacillus plantarum ZDY 2013 and its modulatory effect on gut microbiota of mice. J Dairy Sci. 2015;98:5850-61 pubmed publisher
    ..Lactobacillus plantarum ZDY 2013 was sensitive to some antibiotics (e.g., macrolide, sulfonamides, aminoglycoside, tetracyclines and β-lactams), whereas it was resistant to glycopeptides, quinolones, and ..
  33. Feng M, Tang B, Liang S, Jiang X. Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry. Curr Top Med Chem. 2016;16:1200-16 pubmed
    ..b>Sulfonamides, thioethers, sulfones and Penicillin are the most common scaffolds in sulfur containing drugs, which are well ..
  34. Kim S, Jung K, Son M, Park J, Yan H, Fang Z, et al. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery. Cancer Lett. 2017;403:339-353 pubmed publisher
  35. Akuta N, Kobayashi M, Suzuki F, Sezaki H, Fujiyama S, Kawamura Y, et al. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. Oncology. 2016;91:341-347 pubmed
    ..Liver fibrosis and body mass index, but not treatment regimen, are important predictors of hepatocarcinogenesis following eradication of HCV RNA by direct-acting antivirals. ..
  36. Krasavin M, Korsakov M, Dorogov M, Tuccinardi T, Dedeoglu N, Supuran C. Probing the 'bipolar' nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms. Eur J Med Chem. 2015;101:334-47 pubmed publisher
  37. Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016;7:4428-41 pubmed publisher
    ..Therefore, CCL2 and miRNAs are potential prognostic factors and attractive targets for counteracting treatment resistance in metastatic melanoma. ..
  38. Wen Q, Yang L, Duan R, Chen Z. Monitoring and evaluation of antibiotic resistance genes in four municipal wastewater treatment plants in Harbin, Northeast China. Environ Pollut. 2016;212:34-40 pubmed publisher
    ..and removal efficiency of intI1 and eight subtypes of antibiotic resistance genes (ARGs) for tetracycline, sulfonamides, beta-lactams resistance in four municipal wastewater treatment plants (WWTPs) in Harbin, which locates in ..
  39. Zhao X, Sun W, Puszyk W, Wallet S, Hochwald S, ROBERTSON K, et al. Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma. Tumour Biol. 2017;39:1010428317699120 pubmed publisher
    ..Our data provide fundamental evidence to support the notion that lexatumumab and PF573228 co-treatment could be a potentially effective regime for patients with pancreatic cancer. ..
  40. Lad N, Kulkarni S, Sharma R, Mascarenhas M, Kulkarni M, Pandit S. Piperlongumine derived cyclic sulfonamides (sultams): Synthesis and in vitro exploration for therapeutic potential against HeLa cancer cell lines. Eur J Med Chem. 2017;126:870-878 pubmed publisher
    ..the first time herein we report the synthesis and biological evaluation of the natural product derived cyclic sulfonamides using Grubbs second generation catalyst (Grubbs II) via ring closing metathesis approach...
  41. Thelemann J, Illarionov B, Barylyuk K, Geist J, Kirchmair J, Schneider P, et al. Aryl Bis-Sulfonamide Inhibitors of IspF from Arabidopsis thaliana and Plasmodium falciparum. ChemMedChem. 2015;10:2090-8 pubmed publisher
    ..assay, a screen of 40 000 compounds on IspF from Arabidopsis thaliana afforded symmetrical aryl bis-sulfonamides that inhibit IspF from A...
  42. Krasavin M, Korsakov M, Zvonaryova Z, Semyonychev E, Tuccinardi T, Kalinin S, et al. Human carbonic anhydrase inhibitory profile of mono- and bis-sulfonamides synthesized via a direct sulfochlorination of 3- and 4-(hetero)arylisoxazol-5-amine scaffolds. Bioorg Med Chem. 2017;25:1914-1925 pubmed publisher
    Three distinct series of isoxazole-based primary mono- and bis-sulfonamides have been synthesized via direct sulfochlorination, each of them delivering nanomolar inhibitors of human carbonic anhydrase...
  43. Ji J, Liu Z, Liu P, Sun P. Synthesis of sulfonamides via copper-catalyzed oxidative C-N bond cleavage of tertiary amines. Org Biomol Chem. 2016;14:7018-23 pubmed publisher
    ..b>Sulfonamides were synthesized using this strategy in moderate to good yields...
  44. Yao Z, Yaeger R, Rodrik Outmezguine V, Tao A, Torres N, Chang M, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548:234-238 pubmed publisher
    ..We have thus defined three distinct functional classes of BRAF mutants in human tumours. The mutants activate ERK signalling by different mechanisms that dictate their sensitivity to therapeutic inhibitors of the pathway...
  45. Feßler A, Schwarz S. Antimicrobial Resistance in Corynebacterium spp., Arcanobacterium spp., and Trueperella pyogenes. Microbiol Spectr. 2017;5: pubmed publisher
    ..g., ?-lactams, macrolides, lincosamides, tetracyclines, aminoglycosides, phenicols, sulfonamides/diaminopyrimidines, and fluoroquinolones) have been described...
  46. Ahmadi M, van Hoeven L, Bokhoven K. [From facial pain to toxic epidermal necrolysis: a rare complication of carbamazepine usage]. Ned Tijdschr Geneeskd. 2017;161:D1895 pubmed
    ..is a rare disease that is characterised by epidermal loss, often as a result of medication use - particularly sulfonamides and anti-epileptics...
  47. Męczykowska H, Stepnowski P, Caban M. Effect of salinity and pH on the calibration of the extraction of pharmaceuticals from water by PASSIL. Talanta. 2018;179:271-278 pubmed publisher
    ..of salinity and pH on the PASSIL calibration (sampling rate determination) and the extraction efficiencies of sulfonamides, beta-blockers and nonsteroidal anti-inflammatory drugs selected as model contaminants...
  48. Liu L, Hu S, Shen G, Farooq U, Zhang W, Lin S, et al. Adsorption dynamics and mechanism of aqueous sulfachloropyridazine and analogues using the root powder of recyclable long-root Eichhornia crassipes. Chemosphere. 2018;196:409-417 pubmed publisher
    ..R.E.C.) as a biosorbent to remove aqueous sulfachloropyridazine (SCP) and other sulfonamides. The adsorption processes were investigated dependent on multiple measurements, including FT-IR and XPS ..
  49. NGUYEN T, Grigorjeva L, DAUGULIS O. Aminoquinoline-directed, cobalt-catalyzed carbonylation of sulfonamide sp2 C-H bonds. Chem Commun (Camb). 2017;53:5136-5138 pubmed publisher
    We report a method for cobalt-catalyzed, aminoquinoline-directed sp2 C-H bond carbonylation of sulfonamides. The reactions proceed in a dichloroethane solvent, and employ diisopropyl azodicarboxylate as a carbon monoxide source,..
  50. Mukaihara K, Tanabe Y, Kubota D, Akaike K, Hayashi T, Mogushi K, et al. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma. PLoS ONE. 2017;12:e0185321 pubmed publisher
    ..These in vitro and in vivo data suggest that c-MET may be a potential therapeutic target in ASPS, and cabozantinib may be a particularly useful therapeutic option for patients with ASPS, including those with pazopanib-resistant ASPS. ..
  51. Jang H, Lee J, Kim Y, Jeon J, Shin J, Park M, et al. Fate of antibiotic resistance genes and metal resistance genes during thermophilic aerobic digestion of sewage sludge. Bioresour Technol. 2018;249:635-643 pubmed publisher
    ..examines the fate of twenty-three representative antibiotic resistance genes (ARGs) encoding tetracyclines, sulfonamides, quinolones, β-lactam antibiotics, macrolides, florfenicol and multidrug resistance during thermophilic ..
  52. Soriano Correa C, Barrientos Salcedo C, Francisco Márquez M, Sainz Díaz C. Computational study of substituent effects on the acidity, toxicity and chemical reactivity of bacteriostatic sulfonamides. J Mol Graph Model. 2018;81:116-124 pubmed publisher
    Relationships among physicochemical properties, the chemical structure and antibacterial activity of sulfonamides have not been completely explicated yet...
  53. Angapelly S, Ramya P, Angeli A, Monti S, Buonanno M, Alvala M, et al. Discovery of 4-sulfamoyl-phenyl-?-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors. Bioorg Med Chem. 2017;25:539-544 pubmed publisher
    ..pathological conditions such as glaucoma, retinitis pigmentosa and edema was potently inhibited by the lactam-sulfonamides, with KIs in the range of 0.53-51...
  54. Zhao S, Ma X, Fang S, Zhu L. Behaviors of N-ethyl perfluorooctane sulfonamide ethanol (N-EtFOSE) in a soil-earthworm system: Transformation and bioaccumulation. Sci Total Environ. 2016;554-555:186-91 pubmed publisher
    ..467-30.2 (α) and 0.006-0.415 (β) d(-1), respectively. The results provided important information about the behaviors of N-EtFOSE in the soil-earthworm system. ..